Cargando…

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()

Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and mediates ADCC against CD4 + T cell targets infected with CRF_01 AE tier 2 virus. CH58 and ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicely, Nathan I., Wiehe, Kevin, Kepler, Thomas B., Jaeger, Frederick H., Dennison, S. Moses, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Robb, Merlin L., O'Connell, Robert J., Michael, Nelson L., Kim, Jerome H., Liao, Hua-Xin, Munir Alam, S., Hwang, Kwan-Ki, Bonsignori, Mattia, Haynes, Barton F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534707/
https://www.ncbi.nlm.nih.gov/pubmed/26288844
http://dx.doi.org/10.1016/j.ebiom.2015.06.016
_version_ 1782385493762113536
author Nicely, Nathan I.
Wiehe, Kevin
Kepler, Thomas B.
Jaeger, Frederick H.
Dennison, S. Moses
Rerks-Ngarm, Supachai
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Kaewkungwal, Jaranit
Robb, Merlin L.
O'Connell, Robert J.
Michael, Nelson L.
Kim, Jerome H.
Liao, Hua-Xin
Munir Alam, S.
Hwang, Kwan-Ki
Bonsignori, Mattia
Haynes, Barton F.
author_facet Nicely, Nathan I.
Wiehe, Kevin
Kepler, Thomas B.
Jaeger, Frederick H.
Dennison, S. Moses
Rerks-Ngarm, Supachai
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Kaewkungwal, Jaranit
Robb, Merlin L.
O'Connell, Robert J.
Michael, Nelson L.
Kim, Jerome H.
Liao, Hua-Xin
Munir Alam, S.
Hwang, Kwan-Ki
Bonsignori, Mattia
Haynes, Barton F.
author_sort Nicely, Nathan I.
collection PubMed
description Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and mediates ADCC against CD4 + T cell targets infected with CRF_01 AE tier 2 virus. CH58 and other antibodies that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges with polar, basic side amino acid side chains in V2. In an effort to learn how V2 responses develop, we determined the crystal structures of the CH58-UA antibody unliganded and bound to V2 peptide. The structures showed an LCDR2 structurally pre-conformed from germline to interact with V2 residue Lys169. LCDR3 was subject to conformational selection through the affinity maturation process. Kinetic analyses demonstrate that only a few contacts were responsible for a 2000-fold increase in K(D) through maturation, and this effect was predominantly due to an improvement in off-rate. This study shows that preconformation and preconfiguration can work in concert to produce antibodies with desired immunogenic properties.
format Online
Article
Text
id pubmed-4534707
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-45347072015-08-18 Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee() Nicely, Nathan I. Wiehe, Kevin Kepler, Thomas B. Jaeger, Frederick H. Dennison, S. Moses Rerks-Ngarm, Supachai Nitayaphan, Sorachai Pitisuttithum, Punnee Kaewkungwal, Jaranit Robb, Merlin L. O'Connell, Robert J. Michael, Nelson L. Kim, Jerome H. Liao, Hua-Xin Munir Alam, S. Hwang, Kwan-Ki Bonsignori, Mattia Haynes, Barton F. EBioMedicine Original Article Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and mediates ADCC against CD4 + T cell targets infected with CRF_01 AE tier 2 virus. CH58 and other antibodies that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges with polar, basic side amino acid side chains in V2. In an effort to learn how V2 responses develop, we determined the crystal structures of the CH58-UA antibody unliganded and bound to V2 peptide. The structures showed an LCDR2 structurally pre-conformed from germline to interact with V2 residue Lys169. LCDR3 was subject to conformational selection through the affinity maturation process. Kinetic analyses demonstrate that only a few contacts were responsible for a 2000-fold increase in K(D) through maturation, and this effect was predominantly due to an improvement in off-rate. This study shows that preconformation and preconfiguration can work in concert to produce antibodies with desired immunogenic properties. Elsevier 2015-06-20 /pmc/articles/PMC4534707/ /pubmed/26288844 http://dx.doi.org/10.1016/j.ebiom.2015.06.016 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Nicely, Nathan I.
Wiehe, Kevin
Kepler, Thomas B.
Jaeger, Frederick H.
Dennison, S. Moses
Rerks-Ngarm, Supachai
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Kaewkungwal, Jaranit
Robb, Merlin L.
O'Connell, Robert J.
Michael, Nelson L.
Kim, Jerome H.
Liao, Hua-Xin
Munir Alam, S.
Hwang, Kwan-Ki
Bonsignori, Mattia
Haynes, Barton F.
Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
title Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
title_full Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
title_fullStr Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
title_full_unstemmed Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
title_short Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
title_sort structural analysis of the unmutated ancestor of the hiv-1 envelope v2 region antibody ch58 isolated from an rv144 vaccine efficacy trial vaccinee()
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534707/
https://www.ncbi.nlm.nih.gov/pubmed/26288844
http://dx.doi.org/10.1016/j.ebiom.2015.06.016
work_keys_str_mv AT nicelynathani structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT wiehekevin structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT keplerthomasb structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT jaegerfrederickh structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT dennisonsmoses structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT rerksngarmsupachai structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT nitayaphansorachai structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT pitisuttithumpunnee structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT kaewkungwaljaranit structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT robbmerlinl structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT oconnellrobertj structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT michaelnelsonl structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT kimjeromeh structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT liaohuaxin structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT muniralams structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT hwangkwanki structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT bonsignorimattia structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee
AT haynesbartonf structuralanalysisoftheunmutatedancestorofthehiv1envelopev2regionantibodych58isolatedfromanrv144vaccineefficacytrialvaccinee